Skip to main
AMPH

Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma (AMPH) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Amphastar Pharmaceuticals Inc. reported a solid third-quarter performance with a top-line revenue of $191.8 million, reflecting a 10% quarter-over-quarter and 5% year-over-year increase, surpassing market expectations. The company's Baqsimi and Primatene Mist products exhibited strong sales growth, with Baqsimi experiencing a notable 20% quarter-over-quarter increase in prescriptions, bolstered by strategic collaborations and seasonal demand. Looking ahead, Amphastar anticipates a return to double-digit growth by 2026, along with positive expectations for new product approvals and launches in the near term, indicating a favorable outlook for the company’s financial performance.

Bears say

Amphastar Pharmaceuticals Inc. faces significant revenue pressures as initial sales for its iron sucrose product have come in at only $2.4 million for the second half of Q3 2025, with revised quarterly expectations now estimated at around $5 million, a substantial drop from previous projections of $60 million due to rising competition and supply chain issues. Additionally, the company anticipates further declines in glucagon sales, which are expected to fall below $70 million by 2026, as competition intensifies in this segment and new market entrants exert downward pressure on pricing and demand. Overall, the outlook for Amphastar's top-line growth has been tempered, with forecasts now suggesting only high-single to low-double-digit growth in 2026, against earlier expectations of robust double-digit increases, further compounding concerns about the company's financial trajectory.

Amphastar Pharma (AMPH) has been analyzed by 6 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amphastar Pharma (AMPH) Forecast

Analysts have given Amphastar Pharma (AMPH) a Hold based on their latest research and market trends.

According to 6 analysts, Amphastar Pharma (AMPH) has a Hold consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amphastar Pharma (AMPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.